BOOK A DEMO

Learn about The Power of 3D Liver Ultrasound for NASH Clinical Trials

Join us virtually on December 1 at 10AMPT/12PM CT/1PM ET at the 5th Annual NASH Summit 2021 to learn about The Power of 3D Liver Ultrasound for NASH Clinical Trials, featuring Dr. Stephen Harrison, Medical Director, Pinnacle Clinical Research & President, Summit Clinical Research; and George Aliphtiras, CEO, Sonic Incytes Medical Corp.

Key takeaways include:

  • Understand the technology behind Velacur, the first handheld 3D liver health assessment solution
  • Learn about the power of 3D liver ultrasound in quantifying stiffness and attenuation in comparison to MR elastography and MRI-PDFF
  • Discover the ways in which Velacur can be a cost-effective tool for liver assessment in clinical trials of promising NASH drugs

Visit https://nash-summit.com/program/full-event-guide/ for more info.

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.

Julia PinterMarketing Director

Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.